The Europe Pharmaceutical Industry in Figures
06.20.2019
The pharmaceutical industry is a key partner in Europe’s fight against disease, developing new treatments and cures for patients across Europe. It is imperative that Europe remains a competitive destination for medical research and development by maintaining, sustaining and developing a predictable, robust regulatory and innovation-supportive incentives environment.

Thanks to advances in science and technology, the research-based pharmaceutical industry is entering an exciting new era in medicines development. Research methods are evolving and we have many promising prospects on the horizon — from the possibilities offered by personalised medicines, to the potential offered by harnessing the power of big data. The innovative pharmaceutical industry is driven by, and drives, medical progress. It aims to turn fundamental research into innovative treatments that are widely available and accessible to patients.

The research-based pharmaceutical industry can play a critical role in restoring Europe to growth and ensuring future competitiveness in an advancing global economy. In 2018 it invested an estimated € 36,500 million in R&D in Europe. It directly employs some 765,000 people.

The main European producing countries are Switzerland, Italy, Germany, France, etc. In 2017, these countries together accounted for more than 50% of the total pharmaceutical production. Moreover, Germany is the main exporter of pharmaceutical products, followed by Switzerland and Belgium. Import flows of this product group go through Germany, Belgium, and Great Britain. The United States remain the EU’s key trading partner in pharmaceuticals trade (34.3% of the EU’s total pharmaceutical exports and 37.4% of total imports). In 2018, China accounted for 6.2% of EU exports and 4.9% of EU imports.


Rapid growth in the market and research environment in emerging economies such as Brazil, China and India, leading to a gradual migration of economic and research activities from Europe to these fast-growing markets. During the period 2014-2018 the Brazilian, Chinese and Indian markets grew by 11.4%, 7.3% and 11.2% respectively compared to an average market growth of 5.0% for the top 5 European Union markets and 7.8% for the US market. In 2018 North America accounted for 48.9% of world pharmaceutical sales compared with 23.2% for Europe. According to the authors, 65.2% of sales of new medicines launched during the period 2013-2018 were on the US market, compared with 17.7% on the European market.


Analytics on topic
Article
05.25.2020
Interactive map: Production impact of COVID-19 on the European auto industry
This interactive map shows the impact of the coronavirus / COVID-19 crisis on the production of motor vehicles for each of the 27 EU member states plus the UK.
Source: European Automobile Manufacturers Association
Article
02.03.2020
Transport: increasing oil consumption and greenhouse gas emissions hamper EU progress towards environment and climate objectives
Mobility plays a key role in the EU economy. However, the EU transport sector still relies heavily on fossil fuels and is responsible for one quarter of Europe’s greenhouse gas (GHG) emissions — a share that keeps growing. In addition, the sector is a significant source of air pollution despite significant progress achieved since 1990, especially of particulate matter (PM) and nitrogen dioxide (NO2), as well as the main source of environmental noise in Europe. Current efforts to limit the sector’s environmental and climate impacts in Europe are not sufficient to meet the EU’s long-term climate and environmental policy objectives.
Source: European Environment Agency